Specifically, because GLP-1 agonists are recommended for patients with T2DM and cardiovascular disorders, a higher cardiovascular risk in the GLP-1 agonist group may remain even after adjusting for important cardiometabolic factors in our study. This evidence concerns the gene GLP1R and cardiovascular disorder.